OncoMatch/Clinical Trials/NCT05182164
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Is NCT05182164 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Association of pembrolizumab + cabozantinib for soft tissue sarcoma adult.
Treatment: Association of pembrolizumab + cabozantinib — Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Osteosarcoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced disease
Recurrent disease or progression after standard therapy
Cannot have received: anti-PD-1 therapy (pembrolizumab)
Previous treatment with Pembrolizumab or Cabozantinib; Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: anti-PD-L2 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: anti-CD137 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: anti-CTLA-4 therapy (ipilimumab)
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: VEGFR inhibitor (cabozantinib)
Previous treatment with Pembrolizumab or Cabozantinib
Lab requirements
Blood counts
Adequate hematological function required
Kidney function
Adequate renal function required
Liver function
Adequate hepatic function required
Adequate hematological, renal, metabolic and hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify